Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection

详细信息    查看全文

• 作者：Chayanee Setthapramote ; Tadahiro Sasaki ; Orapim Puiprom ; Kriengsak Limkittikul ; Pannamthip Pitaksajjakul ; Chonlatip Pipattanaboon ; Mikiko Sasayama ; Pornsawan Leuangwutiwong ; Weerapong Phumratanaprapin ; Supat Chamnachanan ; Teera Kusolsuk ; Akanitt Jittmittraphap ; Azusa Asai ; Juan Fern ; o Arias ; Itaru Hirai ; Motoki Kuhara ; Yoshinobu Okuno ; Takeshi Kurosu ; Pongrama Ramasoota ; Kazuyoshi Ikuta ; et al.
• 关键词：Dengue virus ; Human monoclonal antibodies ; Peripheral blood mononuclear cell ; Acute phase ; Secondary infection
• 刊名：Biochemical and Biophysical Research Communications
• 出版年：2012
• 出版时间：13 July, 2012
• 年：2012
• 卷：423
• 期：4
• 页码：867-872
• 全文大小：635 K

文摘

The global spread of the four dengue virus serotypes (DENV-1 to -4) has made this virus a major and growing public health concern. Generally, pre-existing neutralizing antibodies derived from primary infection play a significant role in protecting against subsequent infection with the same serotype. By contrast, these pre-existing antibodies are believed to mediate a non-protective response to subsequent heterotypic DENV infections, leading to the onset of dengue illness. In this study, we prepared hybridomas producing human monoclonal antibodies (HuMAbs) against DENV using peripheral blood mononuclear cells (PBMCs) from patients in the acute phase (around 1 week after the onset of illness) or the convalescent phase (around 2 weeks after the onset of illness) of secondary infection. Interestingly, a larger number of hybridoma clones was obtained from patients in the acute phase than from those in the convalescent phase. Most HuMAbs from acute-phase infections were cross-reactive with all four DENV serotypes and showed significant neutralization activity to all four DENV serotypes. Thus, secondary DENV infection plays a significant role in stimulating memory cells to transiently increase the number of antibody-secreting plasma cells in patients in the early phase after the secondary infection. These HuMAbs will enable us to better understand the protective and pathogenic effects of DENV infection, which could vary greatly among secondarily-infected individuals.